These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 25281400)

  • 1. Pharmacokinetics and safety of rifabutin in young HIV-infected children receiving rifabutin and lopinavir/ritonavir.
    Moultrie H; McIlleron H; Sawry S; Kellermann T; Wiesner L; Kindra G; Gous H; Van Rie A
    J Antimicrob Chemother; 2015 Feb; 70(2):543-9. PubMed ID: 25281400
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomised pharmacokinetic trial of rifabutin with lopinavir/ritonavir-antiretroviral therapy in patients with HIV-associated tuberculosis in Vietnam.
    Lan NT; Thu NT; Barrail-Tran A; Duc NH; Lan NN; Laureillard D; Lien TT; Borand L; Quillet C; Connolly C; Lagarde D; Pym A; Lienhardt C; Dung NH; Taburet AM; Harries AD
    PLoS One; 2014; 9(1):e84866. PubMed ID: 24465443
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetic study of two different rifabutin doses co-administered with lopinavir/ritonavir in African HIV and tuberculosis co-infected adult patients.
    Kouanda S; Ouedraogo HG; Cisse K; Compaoré TR; Sulis G; Diagbouga S; Roggi A; Tarnagda G; Villani P; Sangare L; Simporé J; Regazzi M; Matteelli A
    BMC Infect Dis; 2020 Jun; 20(1):449. PubMed ID: 32590942
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and efficacy of rifabutin among HIV/TB-coinfected children on lopinavir/ritonavir-based ART.
    Rawizza HE; Darin KM; Oladokun R; Brown B; Ogunbosi B; David N; Akanmu S; Olaitan O; Chang C; Scarsi KK; Okonkwo P; Kanki PJ
    J Antimicrob Chemother; 2019 Sep; 74(9):2707-2715. PubMed ID: 31139825
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized pharmacokinetic evaluation of different rifabutin doses in African HIV- infected tuberculosis patients on lopinavir/ritonavir-based antiretroviral therapy.
    Naiker S; Connolly C; Wiesner L; Kellerman T; Reddy T; Harries A; McIlleron H; Lienhardt C; Pym A
    BMC Pharmacol Toxicol; 2014 Nov; 15():61. PubMed ID: 25406657
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Population pharmacokinetics of rifabutin among HIV/TB co-infected children on lopinavir/ritonavir-based antiretroviral therapy.
    Semere Gebreyesus M; Wasmann RE; McIlleron H; Oladokun R; Okonkwo P; Wiesner L; Denti P; Rawizza HE
    Antimicrob Agents Chemother; 2024 Aug; 68(8):e0035424. PubMed ID: 39037240
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics of plasma lopinavir and ritonavir in tuberculosis-HIV co-infected African adult patients also receiving rifabutin 150 or 300 mg three times per week.
    Ouedraogo HG; Matteelli A; Sulis G; Compaore TR; Diagbouga S; Tiendrebeogo S; Roggi A; Cisse K; Giorgetti PF; Villani P; Sangare L; Simpore J; Regazzi M; Kouanda S
    Ann Clin Microbiol Antimicrob; 2020 Jan; 19(1):3. PubMed ID: 31969147
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rifabutin pharmacokinetics and safety among TB/HIV-coinfected children receiving lopinavir/ritonavir-containing second-line ART.
    Rawizza HE; Oladokun R; Ejeliogu E; Oguche S; Ogunbosi BO; Agbaji O; Odaibo G; Imade G; Olaleye D; Wiesner L; Darin KM; Okonkwo P; Kanki PJ; Scarsi KK; McIlleron HM
    J Antimicrob Chemother; 2021 Feb; 76(3):710-717. PubMed ID: 33294914
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Determination of rifabutin dosing regimen when administered in combination with ritonavir-boosted atazanavir.
    Zhang J; Zhu L; Stonier M; Coumbis J; Xu X; Wu Y; Arikan D; Farajallah A; Bertz R
    J Antimicrob Chemother; 2011 Sep; 66(9):2075-82. PubMed ID: 21712242
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of super-boosted lopinavir/ritonavir in combination with rifampicin in HIV-1-infected patients with tuberculosis.
    Boulanger C; Rolla V; Al-Shaer MH; Peloquin C
    Int J Antimicrob Agents; 2020 Feb; 55(2):105840. PubMed ID: 31704214
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and Pharmacokinetics of Double-Dose Lopinavir/Ritonavir + Rifampin Versus Lopinavir/Ritonavir + Daily Rifabutin for Treatment of Human Immunodeficiency Virus-Tuberculosis Coinfection.
    Kendall MA; Lalloo U; Fletcher CV; Wu X; Podany AT; Cardoso SW; Ive P; Benson CA
    Clin Infect Dis; 2021 Aug; 73(4):706-715. PubMed ID: 34398956
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of rifabutin in Japanese HIV-infected patients with or without antiretroviral therapy.
    Tanuma J; Sano K; Teruya K; Watanabe K; Aoki T; Honda H; Yazaki H; Tsukada K; Gatanaga H; Kikuchi Y; Oka S
    PLoS One; 2013; 8(8):e70611. PubMed ID: 23940604
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protease inhibitor-containing antiretroviral treatment and tuberculosis: can rifabutin fill the breach?
    Loeliger A; Suthar AB; Ripin D; Glaziou P; O'Brien M; Renaud-Thery F; Crowley S; Williams B; Ridzon R; Granich R; Gilks C
    Int J Tuberc Lung Dis; 2012 Jan; 16(1):6-15. PubMed ID: 21819645
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of rifampicin on lopinavir pharmacokinetics in HIV-infected children with tuberculosis.
    Ren Y; Nuttall JJ; Egbers C; Eley BS; Meyers TM; Smith PJ; Maartens G; McIlleron HM
    J Acquir Immune Defic Syndr; 2008 Apr; 47(5):566-9. PubMed ID: 18197120
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetic evaluation of rifabutin in combination with lopinavir-ritonavir in patients with HIV infection and active tuberculosis.
    Boulanger C; Hollender E; Farrell K; Stambaugh JJ; Maasen D; Ashkin D; Symes S; Espinoza LA; Rivero RO; Graham JJ; Peloquin CA
    Clin Infect Dis; 2009 Nov; 49(9):1305-11. PubMed ID: 19807276
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics of rifabutin during atazanavir/ritonavir co-administration in HIV-infected TB patients.
    Ramachandran G; Hemanth Kumar AK; Kannan T; Sridhar R; Guha SK; Kadam D; Poorana Gangadevi N; Rajapandian T
    Indian J Tuberc; 2019 Jan; 66(1):129-133. PubMed ID: 30797270
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Coadministration of lopinavir/ritonavir and rifampicin in HIV and tuberculosis co-infected adults in South Africa.
    Murphy RA; Marconi VC; Gandhi RT; Kuritzkes DR; Sunpath H
    PLoS One; 2012; 7(9):e44793. PubMed ID: 23028623
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Paediatric abacavir-lamivudine fixed-dose dispersible tablets and ritonavir-boosted lopinavir granules in neonates exposed to HIV (PETITE study): an open-label, two-stage, single-arm, phase 1/2, pharmacokinetic and safety trial.
    Bekker A; Salvadori N; Rabie H; du Toit S; Than-In-At K; Groenewald M; Cressey R; Nielsen J; Capparelli EV; Lallemant M; Cotton MF; Cressey TR;
    Lancet HIV; 2024 Feb; 11(2):e86-e95. PubMed ID: 38296364
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lopinavir pharmacokinetic profiles in HIV-infected patients during rifabutin-based anti-mycobacterial therapy.
    Matteelli A; Villani P; Carvalho AC; El-Hamad I; Cusato M; Apostoli A; Marcantoni C; Calabresi A; Dal Zoppo S; Bigoni S; Regazzi M
    J Antimicrob Chemother; 2012 Oct; 67(10):2470-3. PubMed ID: 22678727
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics of rifabutin during atazanavir/ritonavir co-administration in HIV-infected TB patients in India.
    Ramachandran G; Bhavani PK; Hemanth Kumar AK; Srinivasan R; Raja K; Sudha V; Venkatesh S; Chandrasekaran C; Swaminathan S
    Int J Tuberc Lung Dis; 2013 Dec; 17(12):1564-8. PubMed ID: 24200269
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.